UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM SD
Specialized Disclosure Report
ABIOMED, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware | 001-09585 | 04-2743260 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
22 Cherry Hill Drive, Danvers, Massachusetts | 01923 | |
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code (978) 646-1400
Robert L. Bowen
978-646-1400
(Name and telephone number, including area code, of the person to contact in connection with this report)
Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
x | Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2014. |
Section 1 Conflict Minerals Disclosure
Item 1.01 Conflict Minerals Disclosure and Report
Conflict Minerals Disclosure
This Form SD of ABIOMED, Inc. (the Company) is filed pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period January 1, 2014 to December 31, 2014.
Based on our reasonable country of origin inquiry and due diligence, we concluded that certain of our products are DRC Conflict Undeterminable as defined in Rule 13p-1, and as a result, we have filed a Conflict Minerals Report.
A copy of our Conflict Minerals Report is filed herewith as Exhibit 1.01 hereto and is publicly available at: www.abiomed.com.
Information appearing on www.abiomed.com is not a part of, and is not incorporated by reference into, this Form SD.
Item 1.02 Exhibit
As specified in Section 2, Item 2.01 of this Form SD, the Company is hereby filing its Conflict Minerals Report as Exhibit 1.01 to this Report.
Section 2 Exhibits
Item 2.01 Exhibits
The following exhibit is filed as part of this report:
Exhibit 1.01 Conflict Minerals Report as required by Item 1.01 and 1.02 of this Form SD.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 1, 2015 | ABIOMED, INC. (Registrant) | |||||
By: | /s/ Robert L. Bowen | |||||
Robert L. Bowen | ||||||
Chief Financial Officer |